Recent Events

Irish Academy of Medical Sciences meeting to initiate actions to address the crisis in medical staffing in Irish Healthcare.

As you are aware there is an obvious and increasing crisis in the availability and retention of medical staff in Irish healthcare.  In that context, the Irish Academy of Medical Sciences is undertaking a series of activities to ensure that the necessary urgency is given to addressing what is one of the most significant challenges facing the health service.

A major focus of these activities will be the identification of actions and initiatives to create an environment which will ensure that a resolution of this crisis is successfully achieved.

The initial step will be organisation of a major meeting which will involve representation from all who are impacted upon by the lack of medical resources. The meeting  will take place on

Wednesday 8th March 2017 at 19.00, in the Cheyne Theatre, Royal College of Surgeons, 123 St Stephen’s Green, Dublin 2.

The meeting will consist of formal presentations to be followed with a moderated open forum to provide for interaction, participation and input for all attending.

Topics to be included in the formal presentations will include:

  • Reports on the current situation within clinical service provision and the impact of the lack of clinical resources
  • Reviews of previous proposals to address these problems
  • Reviews of implementation of these proposals
  • Identification of  issues and areas which inhibit a  resolution of the crisis
  • Necessary actions to eliminate or minimise the inhibitors of a successful resolution of the crisis

Speakers providing formal presentations are:

Professor  Brian MacCraith, President DCU, Chairperson of Strategic review of medical training and career structure

Professor Eilis McGovern, National Programme Director for Medical Education, Medical

Education and Training Unit, HSE

Professor Ruairi Brugha, Head of the Department of Epidemiology and Public Health Medicine, RCSI

Dr Ciara Gough, NCHD, Specialist registrar, Pulmonary medicine, Beaumont hospital

Professor Noel G McElvaney, President of Irish Academy of Medical Sciences, Professor of Medicine RCSI

It is intended that the deliberations and the outcomes from the meeting, in addition to providing input to support the Academy’s actions in addressing this crisis, will also be widely disseminated.

Annual Scientific Symposium 2015

The Irish Academy of Medical Sciences’ Annual Scientific Symposium will take place on Tuesday 1st December 2015 in the Albert Lecture Theatre, RCSI, St. Stephens’s Green, Dublin 2.

The theme for this year’s Symposium is

“Ireland as a world class centre of excellence for clinical research – Opportunities, issues and challenges”

Morning Session  (09.00 -12.50) The environment for clinical research in the context of the current and planned governance, strategy, management and delivery of Irish healthcare.

Afternoon Session (13.45 – 15.45) Enabling the optimum environment  for  clinical research in Ireland

See below for complete speaker schedule

The Symposium is complimentary and as spaces are limited,   pre-registration is strongly recommended.

You can pre-register by  e mailing your name, work address, contact telephone number and e mail address  to


09.00 – 09.10:  Welcome – Professor Noel G. McElvaney, President, Irish Academy of Medical Sciences

09.10 – 09.35:   Mr. Dermot Mulligan, Assistant Secretary for Innovation and Investment,   Department of Jobs, Enterprise & Innovation

09.35 – 10.00:   Dr. Graham Love, Chief Executive, Health Research Board

10.00 – 10.25:   Dr. Rebecca Cramp, Scientific and Regulatory Affairs Manager, Irish   Pharmaceutical   Healthcare Association

10.25 – 10.50:   Mr. Muiris O’Connor, Assistant Secretary for Research & Development and Health   Analytics, Department of Health

11.00   – 11.30: Tea/Coffee

11.30 -11.55:   Professor Orla Hardiman, Professor of Neurology, Trinity College Dublin

11.55– 12.20:  Dr. Colm Gilligan, Medical Director, MSD Ireland

12.20 – 12.45:  Mr. Thomas Lynch, Chairperson for the Dublin East Hospital Group

12.45  – 13.45:   Lunch

13.45 – 14.10:   Professor Arnold Hill, Head of School of MedicineProfessor of Surgery, Royal College of   Surgeons in Ireland

14.10 – 14. 35:   Professor Michael Gill, Clinical Director, Wellcome Trust/HRB CRF St. James’ Hospital   Trinity Centre for Health Sciences

14.35 -15.45   Academy Working Groups  – Updates and feedback

  • “The establishment of the optimum data & information environment for   Healthcare in Ireland” – Presented and facilitated by Professor Elaine Kay, Professor of Pathology  &   Consultant Histopathologist,  Royal College of Surgeons in Ireland
  • “The establishment of the optimum ethical environment for Healthcare Research in   Ireland” – Presented and facilitated by Professor David Smith, Professor of Health Care Ethics Department of General PracticeRoyal College of Surgeons in Ireland
  • “Clinical Trial Research: Value to Ireland” – Presented and facilitated TBC

Potential implications for Research Funding arising from the European Commission’s proposal in regard to the European Fund for Strategic Investment (EFSI)

The Academy has written to the Minister for  Health and the Irish MEPs  to draw their  attention to the implications of the European Commission’s proposal in regard to funding the European Fund for Strategic Investment (EFSI)

The European Commission proposes to cut €2.7 billion from Horizon 2020 to finance EFSI. This equals a cut of 3.5% to an EU programme that already has one of the smallest budgets – yet research has a vital part to play in keeping Europe healthy and competitive. Investment in the European Research Council (ERC), one of the most important funders of excellent basic research, the Marie Skłodowska- Curie Actions,that support early-career researchers, and researchers’ access to infrastructure across Europe would all be cut.

The Academy notes the European Commission’s intention is for EFSI to also fund research projects. However, there is no formal obligation in place to ensure funds taken from Horizon 2020 is channelled back into research and innovation and it is  concerned that many organisations that conduct research – including universities, research funders, research performing organisations, charities and health services – may not be eligible for EFSI funding under the proposed wording. There is therefore a real danger of funding agreed to be for research being diverted to other purposes. EFSI is supposed to be of great benefit to the real economy. This is of great concern because research is a prerequisite for innovation, without research the pipeline to innovation is cut off. Research must be publicly funded in an appropriate way and any cuts to Horizon 2020 will result in a performance loss for the whole European research and innovation system.

Europe needs long-term, reliable and adequate funding for excellent research by the EU to deliver sustainable growth and jobs and improve the health of people living in Europe. Accordingly, in response to the European Commission’s proposal for funding the EFSI, the Academy is requesting that all Irish MEPs and the Irish Government, swiftly and assertively take steps to protect investment in Horizon 2020 and so in Irish research.

In particular the Academy has requested the Government and MEPs   to support:

  • A reversal in the cuts to Horizon 2020.
  • A formal guarantee that adequate funding in EFSI is channelled directly   into research and innovation to ensure that money committed to fund    research is not diverted to other purposes.

•           A prerequisite that funding to research and innovation projects will be   allocated competitively and on the basis of excellence

Federation of European Academies of Medicine  (FEAM) Symposium  13 May 2015, Paris: “Adolescent health: investing in the future”

Singer-Polignac Foundation, 43 Avenue Georges Mandel, 75116 Paris, France

This Symposium will explore adolescence as an important gateway to adult diseases and the focus will be the topical issues of adolescent mental health and obesity. Leading biomedical experts from across Europe will present and discuss the current scientific evidence in terms of health promotion, disease prevention, and the evaluation of genetic and environmental risk factors.

It is organised by FEAM and the French Academy of Medicine with the support of FAM(Foundation of the French Academy of Medicine) and the Singer-Polignac Foundation

Further information is available on the FEAM website –


Annual Symposium 2014 – Programme, Speaker presentation titles and short biographies


Registration/Tea/Coffee – 10.00 – 11.00

Welcome: Professor Gerard McElvaney, President Irish Academy of MedicalSciences

Session 1:11.00-13.00

Session Chairs: Mr Gerard Hurl (IAMS), Professor Joseph Keane (TCD)

“Building a Clinical Trials Infrastructure in Ireland”
Dr. Graham Love, Health Research Board (HRB)

“Ethical Review of Clinical Research”
Professor Bernard Charpentier, Vice-President, FEAM.

“Post-hoc Research on Data – Samples without consent – Research Ethics Committee at the apex of uncertainty”
Ms Gillian Vale, Beaumont Hospital Dublin

“Research Access to Confidential Patient Information: What can we reasonably expect?”
Dr. Mark Taylor, University of Sheffield

Lunch: 13.00-14.00

Session 2:   14.00-16.00

Session Chairs: Professor Seamas Donnelly (UCD), Professor Gerry McElvaney (RCSI)

“Helminths as anti-inflammatory therapies: worms on trial?”
Professor Padraic Fallon, Trinity College

“Novartis program to radically improve clinical trials: Trials of The Future”
Dr Andy Brown, Global Head, Clinical Trials of the Future, Novartis.

“The Challenges of Translational Science”
Professor Garret FitzGerald, University of Pennsylvania.


Prof. B. Charpentier – “Ethical Review of Clinical Research: presentation of the outcomes of a FEAM Workshop”

Prof. B. Charpentier received his MD and graduated in Nephrology from Paris University School of Medicine in 1975. He is full Professor in Medicine in Paris-Sud 11 University since 1983, medical Consultant and was Head of the Department of Nephrology, Dialysis and Transplantations in the University Hospital of Bicêtre (1992-2011). He was Director of several CNRS-INSERM-University Paris-Sud 11 research units devoted to Immunology and Immunoregulation (CNRS UPR 277-420; INSERM U542-1014). He is (co)author of more than 400 pubmed-indexed publications on Nephrology and Transplantation. He was member of several Editorial Boards of immunology and transplantation journals and of immunology, nephrology, and transplantation societies. He acts as a consultant for several International, European and National Advisory Committees. He is member of the Ethical and Sanction Committee (CODEEM) (2011-2014) of the French Pharmaceutical Companies Union (LEEM).

He was Dean of the Faculty of Medicine Paris-Sud (1998-2008), President of the French Medical Deans’ Council (2003-2008), President of the French Transplant Society (1997-2000), President of the European Society for Organ Transplantation (ESOT) (2005-2007), Co-Chairman of the XVth ESOT Congress (Paris-2009). He was elected as full member of the French Academy of Medicine (2010), Council Member of the Federation of European Academies of Medicine (FEAM-2012) and now FEAM Vice-President (2014). He is Officier de la Légion d’Honneur, Officier de l’Ordre du Mérite, Chevalier des Palmes Académiques, Médaille d’Honneur du Service de Santé des Armées.
His field of interest are mainly focused in transplantation medicine, basic immunology, immunoregulation and immunosuppressive drugs.

Professor Garret Fitzgerald – “Adventures in Translational Science”

Dr. Garret FitzGerald is the McNeil Professor in Translational Medicine and Therapeutics at the University of Pennsylvania in Philadelphia, where he chairs the Department of Pharmacology and directs the Institute for Translational Medicine and Therapeutics. Dr. FitzGerald’s research has been characterized by an integrative approach to elucidating the mechanisms of drug action, drawing on work in cells, model organisms and humans. His work contributed substantially to the development of low-dose aspirin for cardioprotection. FitzGerald’s group was the first to predict and then mechanistically explain the cardiovascular hazard from NSAIDs. He has also discovered many products of lipid peroxidation and established their utility as indices of oxidant stress in vivo. His laboratory was the first to discover a molecular clock in the cardiovascular system and has studied the importance of peripheral clocks in the regulation of cardiovascular and metabolic function. Dr. FitzGerald has received the Boyle, Coakley, Harvey and St. Patrick’s Day medals, the Lucian, Scheele and Hunter Awards and the Cameron, Taylor, Herz, Lefoulon-Delalande, and Schottstein Prizes. He is a member of the Institute of Medicine and a Fellow of the American Academy of the Arts and Sciences and of the Royal Society.

Dr. Graham Love – Chief Executive,  Health Research Board

Dr. Graham Love is Chief Executive of the Health Research Board, an agency of the Irish Government’s Department of Health. The HRB manages a €100+ million investment portfolio spanning clinical, population and health services research. It also manages key health information systems and provides evidence-based policy support to the (Irish) Government’s Department of Health. Previously Graham worked in Science Foundation Ireland, covering a variety of areas including strategy, communications and programmes, where he filled senior roles such as Head of Strategy, Director of Policy and Interim Director General. Before entering the Public Service, Graham was in the private sector for many years working for management consulting firm Accenture. There he worked with international clients such as Microsoft, Vodafone and Norsk Hydro on a range of projects including IT system implementations, strategic reviews and transformational change.
He lives with his family in Dublin.

Dr.Andy Brown

Dr Andy Brown is Global Program Head – Trials of The Future at Novartis Pharma, where he leads 9 workstreams to develop new technologies and models that will radically improve clinical trials and the patient experience: 1) Patient recruitment 2) Drug Delivery eDevices, 3) Sensors, 4) Telehealth,  5) ePRO/eSource, 6) Data visualization, 7) Novel Settings, 8) Sourcing, and 9) Communications.

Prior to this Andy was a UK and European Pharma R&D Lead at PricewaterhouseCoopers management consulting. He has over 20 years of successful direction and delivery of major international new product development and R&D performance improvement projects, having worked with many of the world’s leading Pharmaceutical companies. Early in his career he was one of the clinical leads for Wellcome’s alpha-interferon trial programme in Hepatitis B/C, and was a principal clinical author of the successful licence application for Hepatitis B. At Pharmacia he led one of the fastest clinical studies in company history in response to serious post-launch adverse events. In addition he has started, developed and sold his own technology-based business, and as VP Global R&D, Andy directed new product development strategy and execution at Thomson Scientific’s pharmaceutical business. Andy has a  BSc (Joint Hons) Zoology/Microbiology, a PhD in Cellular Immunology, an MBA, completed a BSc (Hons) Psychology in 2010, and is studying for an MSc in Occupational Psychology. He is a rugby fan, and looks forward to England winning the World Cup again in 2015

Ms. Gillian Vale

Ms. Gillian Vale has been the administrator of the research ethics committee at Beaumont Hospital since 2005.   She is responsible for co-ordinating the administrative functions of this committee, and is the primary point of contact for applicants.  Beaumont Hospital Ethics (Medical Research) Committee provides a professional research ethics committee service to applicants (academic, industry, charity, other) seeking to conduct research in Beaumont Hospital and the Royal College of Surgeons Clinical Research Centre.

She has been a guest lecturer in the Royal College of Surgeons in Ireland, teaching undergraduate and postgraduate students about the practicalities of applying for research ethics committee approval.

She attended University College Dublin, and graduated with a Bachelor of Arts (Hons) Degree in 1993, and a Higher Diploma in Education in 1994.   She holds an MSc in Healthcare Ethics and Law from the Royal College of Surgeons in Ireland (2008).She is a past member of the European Commission ‘ad hoc group for the development of implementing guidelines for the “clinical trials directive” 2001/20/EC’ (2010 – 2011), and a current member of the Research Ethics Committee Standard Application Form (RECSAF) Consultation Group (2009 – current).

Dr. Mark Taylor

Dr Mark Taylor is a Senior Lecturer in the School of Law at the University of Sheffield and Deputy Director of the Sheffield Institute of Biotechnology, Law and Ethics (SIBLE). He specialises in health information law, privacy and legal and ethical conceptions of the public interest. Author of ‘Genetic Data and the Law’ (CUP, 2012), he is a mid-career Fellow of the British Academy, and a Research Associate at the HeLEX Centre for Health, Law and Emerging Technologies at the University of Oxford. He has either led or otherwise contributed to a number of research projects, including currently an EU FP7 project to make policy recommendations for open access to Research Data in Europe (RECODE). He is the establishing Chair of the Confidentiality Advisory Group (CAG). This is an independent expert group providing advice to the Health Research Authority and the Secretary of State for Health on access to confidential health information without patient consent in England and Wales. He is a member of Dame Fiona Caldicott’s Independent Information Governance Oversight Panel. He is a member of the Ethics Advisory Committee to Genomics England. He is also a member of the Privacy and Security Policy Task Team for the Global Alliance for Genomics and Health Care

Professor Padraic Fallon

Padraic G. Fallon is Professor of Translational Immunology, School of Medicine, Trinity College Dublin. His research uses both mouse models and patient studies to elucidate new mechanisms of modulation of immunity that can regulate inflammation and have therapeutic potential.  He completed his PhD in 1995 (University of Wales) in immuno-parasitology, and was awarded a Wellcome Trust Fellowship in University of Cambridge, UK – researching immune-modulating helminth molecules – before returning to Trinity College Dublin in 2001. Fallon leads research programmes in allergic lung and skin inflammation, and inflammatory bowel disease. Since 2007 he has generated over €13 million of funding as Principal Investigator for his research; supporting programme on paediatric immunology and fundamental mechanistic research using animals models of innate and adaptive immunity. Fallon has published over 130 research publications in leading international journals in the field of immunology, including NatureScienceScience Translational MedicineNature ImmunologyNature GeneticsNature CommunicationsJournal of Experimental Medicine, Proceeding of National Academy, and Immunity. Fellow is a Fellow of Trinity College Dublin and was elected a Member of the Royal Irish Academy in 2014.  His research group is based in the Trinity Biomedical Sciences Institute, Trinity College Dublin, Institute of Molecular Medicine, St James’s Hospital and National Children’s Research Centre, Our Lady’s Children’s Hospital, Crumlin